DGAP-News: WILEX AG: UCB gets access to rights for an antibody programme from WILEX for non-oncology indications
(firmenpresse) - DGAP-News: WILEX AG / Key word(s): Alliance
WILEX AG: UCB gets access to rights for an antibody programme from
WILEX for non-oncology indications
10.07.2013 / 06:59
---------------------------------------------------------------------
PRESS RELEASE
UCB gets access to rights for an antibody programme from WILEX for
non-oncology indications
Munich, Germany / Brussels, Belgium, 10 July 2013 - WILEX AG (ISIN
DE0006614720 / WL6 / FSE) and UCB announced today that UCB has acquired an
antibody programme from WILEX' preclinical portfolio originally obtained
from UCB in 2009. UCB has the right to develop the antibodies from the
programme in any indication outside the field of oncology, while WILEX
keeps the rights to develop for oncology indications.
WILEX will be reimbursed an undisclosed amount for its development costs to
date and shall be eligible for future, undisclosed development, regulatory
and commercial milestone payments as well as royalties.
UCB and WILEX will continue to share data regarding the programme through
the existing development committee structures. UCB will be working on these
antibodies in immunology/inflammation and, as part of the strategic
partnership between the two companies, will make available to WILEX the
relevant data to assist WILEX in oncology.
Professor Olaf G. Wilhelm, Chairman of the Executive Management Board of
WILEX AG, commented, 'An identified lead antibody and generated data
attracted UCB to purchase the rights to indications outside oncology at
such an early stage which is not only a validation of our capabilities but
also proof of our excellent partnership with UCB.'
Ismail Kola, Executive Vice President and Chairman of New Medicine at UCB,
said: 'The pre-clinical work originated by UCB and continued by WILEX
researchers to identify the immunology potential of one of their programs
is of great interest to us. Leveraging UCB's scientific expertise in
immunology, we will now take the program forward and explore it further in
immunology indications where there are severe unmet needs.'
About WILEX
WILEX AG is a biopharmaceutical company based in Munich, Germany. Focused
on oncology, the Company develops diagnostic and therapeutic product
candidates for the specific detection and targeted treatment of various
types of cancer. In the field of therapeutics, WILEX develops antibodies
and small molecules. (RENCAREX(R): Phase III, MESUPRON(R): Phase II,
WX-554: Phase Ib/II and WX-037: preclinical). In the field of diagnostics,
REDECTANE(R) is an antibody-based imaging agent that is currently in a
Phase III programme. The Company also has a portfolio of biomarker assays
that are marketed via its US subsidiary WILEX Inc. under the brand Oncogene
Science. WILEX's subsidiary Heidelberg Pharma GmbH offers preclinical
contract research services and a highly promising antibody drug conjugate
(ADC) technology platform. The business model of WILEX comprises research
and product development as well as the commercialisation of its activities.
WILEX's customers and partners include leading international pharmaceutical
companies. Website: http://www.WILEX.com, ISIN DE0006614720 / WKN 661472 /
Symbol WL6.
About UCB
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company
focused on the discovery and development of innovative medicines and
solutions to transform the lives of people living with severe diseases of
the immune system or of the central nervous system. With 9000 people in
approximately 40 countries, the company generated revenue of EUR 3.4
billion in 2012. UCB is listed on Euronext Brussels (symbol: UCB).
Contact
TABLE_START>Katja Arnold (CIRO) Antje Witte / Alexandra Deschner
WILEX AG UCB, Investor Relations
Corporate Communications&IR T +32 2 559 9414, antje.witte(at)ucb.com
Grillparzerstr. 10 T +32 2 559 9683, alexandra.deschner(at)ucb.com
81675 Munich, Germany Allée de la Recherche, 60
Tel.: +49 (0)89-41 31 38-126 1070 Brussels, Belgium
Email: investors(at)wilex.com RPM Brussels 0403.053.608This communication contains certain forward-looking statements relating to
the Company's business, which can be identified by the use of
forward-looking terminology such as 'estimates', 'believes', 'expects',
'may', 'will', 'should', 'future', 'potential' or similar expressions or by
a general discussion of the Company's strategy, plans or intentions. Such
forward-looking statements involve known and unknown risks, uncertainties
and other factors, which may cause our actual results of operations,
financial position, earnings, achievements, or industry results, to be
materially different from any future results, earnings or achievements
expressed or implied by such forward-looking statements. Given these
uncertainties, prospective investors and partners are cautioned not to
place undue reliance on such forward-looking statements. We disclaim any
obligation to update any such forward- looking statements to reflect future
events or developments.
End of Corporate News
---------------------------------------------------------------------
10.07.2013 Dissemination of a Corporate News, transmitted by DGAP - a
company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: WILEX AG
Grillparzerstr. 10
81675 München
Germany
Phone: +49 (0)89 41 31 38 - 0
Fax: +49 (0)89 41 31 38 - 99
E-mail: info(at)wilex.com
Internet: www.wilex.com
ISIN: DE0006614720
WKN: 661472
Listed: Regulierter Markt in Frankfurt (Prime Standard);
Freiverkehr in Berlin, Düsseldorf, München, Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------
220520 10.07.2013
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 10.07.2013 - 06:59 Uhr
Sprache: Deutsch
News-ID 276903
Anzahl Zeichen: 8174
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 311 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: WILEX AG: UCB gets access to rights for an antibody programme from WILEX for non-oncology indications"
steht unter der journalistisch-redaktionellen Verantwortung von
WILEX AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
